RVTY
Revvity, Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$130.52
−0.09%Aug 20, 2026, 00:12 UTC
On August 19, 2026, Revvity Inc's shares surged 5.0% to $119.45, within a 52-week range of $81.22 to $122.11.
Source:Aug 15, 2026, 07:27 UTC
Assenagon Asset Management S.A. reduced its stake in Revvity Inc. by 35.5% during the quarter, selling 8,540 shares, leaving 15,483 shares, as disclosed in a 13F filing.
Source:Aug 13, 2026, 15:01 UTC
Revvity launched SuperFlex, a compact automated prenatal screening system for smaller labs and clinics.
Source:Aug 10, 2026, 12:00 UTC
Revvity, Inc. launched the SuperFlex prenatal screening system, a compact CE-IVDR certified immunoassay instrument for preeclampsia testing, on August 10, 2026.
Source:Aug 4, 2026, 10:00 UTC
Revvity reported financial results for the second quarter ended July 5, 2026, with GAAP earnings per share of $0.48 and revenue of $730 million.
Jul 31, 2026, 20:05 UTC
Revvity, Inc. declared a regular quarterly dividend of $0.07 per share, payable on November 13, 2026 to shareholders of record on October 23, 2026.
Source:Jul 24, 2026, 16:05 UTC
Revvity is developing a high-throughput T-SPOT.TB platform (T-SPOT A201) for clinical labs, targeting a 2027 launch.
Source:Jul 22, 2026, 16:05 UTC
Revvity launched Signals for Startups, a software and onboarding service for early-stage biotech companies.
Jul 20, 2026, 12:00 UTC
Revvity launched the Signals for Startups program to help emerging biotech companies adopt scalable informatics capabilities.
Source:Jul 2, 2026, 15:01 UTC
Revvity expands its Signals AI platform by integrating Anthropic's Claude through the Model Context Protocol ecosystem, providing scientists with secure access to connected R&D data and scientific context.
Source:Jun 22, 2026, 12:00 UTC
Revvity launched Signals AI, a native agentic framework for accelerating scientific R&D, built into the Signals One platform.
Source: